Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Oncology clinical trials

    Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options
    Special Populations

    Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options

    Healthcare providers are less likely to talk to Black patients with metastatic breast cancer about opportunities to enroll in clinical trials than they are with patients from other racial or ethnic backgrounds, researchers reported at the 2022 ASCO Annual Meeting.

    February 01, 2023
    Monica Bertagnolli Delivers First NCI Director’s Report, Outlines Principles to Evolve Cancer Research
    National Cancer Institute (NCI)

    Monica Bertagnolli Delivers First NCI Director’s Report, Outlines Principles to Evolve Cancer Research

    In her first report as National Cancer Institute director, Monica M. Bertagnolli, MD, laid out her eight core principles to guide the agency’s work in reformulating clinical trials and strengthening cancer research during the Clinical Trials Advisory Committee meeting in November 2022.

    November 17, 2022
    Balance Hope and Quality of Life for Phase I Clinical Trials
    Oncology clinical trials

    Balance Hope and Quality of Life for Phase I Clinical Trials

    Leita, a 42-year-old patient with locally advanced pancreatic cancer, was treated with 5-fluorouracil, irinotecan, and oxaliplatin followed by capecitabine and radiation therapy. After she completed initial treatment, a computed tomography scan conducted in preparation for a possible surgical resection revealed metastatic liver lesions. Leita’s surgery was cancelled, and she began second-line therapy with gemcitabine and nab-paclitaxel.

    September 20, 2022
    Drug Clinical Trials Focus on Efficacy Over Quality of Life
    Oncology clinical trials

    Drug Clinical Trials Focus on Efficacy Over Quality of Life

    The clinical trials that lead to new drug approvals or expanded indications are quick to praise a therapy’s clinical benefits, such as longer survival or time to progression, but only about one in five of those trials find improvements in patients’ quality of life, researchers reported in JAMA Oncology.

    September 07, 2022
    Healthcare Organizations Advocate for Clinical Trial Diversity in Letter to Congress
    Clinical practice

    Healthcare Organizations Advocate for Clinical Trial Diversity in Letter to Congress

    Healthcare organizations advocated to improve diversity among clinical trials in a letter sent to U.S. Congress in May encouraging the government to take steps as the reauthorization of the Prescription Drug User Fee Act (PDUFA) approaches. The PDUFA allows the U.S. Food and Drug Administration to review and approve drugs, but the authorization is set to expire in September of 2022.

    June 28, 2022
    NCI Hosts Virtual Roundtable Discussion on Expanding Clinical Trial Accrual
    Oncology clinical trials

    NCI Hosts Virtual Roundtable Discussion on Expanding Clinical Trial Accrual

    Driven by the reignited Cancer Moonshot, the National Cancer Institute (NCI) hosted a virtual roundtable discussion on the possibilities and challenges of increasing clinical trial accrual in May 2022.  

    June 16, 2022
    FDA’s Industry Guidance Will Increase Racial and Ethnic Diversity in Clinical Trials
    Oncology clinical trials

    FDA’s Industry Guidance Will Increase Racial and Ethnic Diversity in Clinical Trials

    New draft guidance from the U.S. Food and Drug Administration (FDA) facilitates enrolling more participants from underrepresented racial and ethnic U.S. populations into industry clinical trials. According to FDA, despite their disproportionate burden for certain diseases, racial and ethnic minorities are frequently underrepresented in research and expanding diversity in clinical trials is an important step to reduce those disparities.

    June 02, 2022
    Advocate for Equal Access for Next Generation Sequencing and Clinical Trials
    Ethics in nursing

    Advocate for Equal Access for Next Generation Sequencing and Clinical Trials

    Janice is an oncology nurse in a rural community cancer center. Only one of the three oncologists in the practice discusses clinical trials with their patients and typically not until after patients complete two to three lines of therapy. Also, the practice does not have a process for when to order next generation sequencing (NGS). Janice feels it is not ethical that the patients coming to the clinic do not have equal access to those important services.

    March 21, 2022
    The Case of the Clinical Trials Consultation
    Oncology clinical trials

    The Case of the Clinical Trials Consultation

    Don, age 72, was diagnosed with borderline resectable pancreatic adenocarcinoma more than a year ago. Genetic testing indicated a BRCA2 variant. He completed 12 cycles of FOLFIRINOX followed by a pancreaticoduodenectomy (Whipple procedure). He had no evidence of disease for six months until a liver lesion seen on surveillance imaging tested positive for metastatic pancreatic cancer. His medical oncologist suggests a clinical trial targeting the BRCA2 variant.

    December 21, 2021
    Help Patients Understand Biomarker Test Results and Clinical Trials Options
    Genetics & genomics

    Help Patients Understand Biomarker Test Results and Clinical Trials Options

    Many of today’s new drug approvals and standard-of-care treatments have a companion diagnostic test that identifies biomarkers in a patient’s tumor tissue or blood to determine whether they are an appropriate candidate for the therapy. When those results show that they’re not a good match for the U.S. Food and Drug Administration (FDA)-approved treatment, the findings may identify a biomarker-directed clinical trial as an alternative option. Here’s how oncology nurses can help patients understand which clinical trials listed on their test results might be an option for them.

    December 16, 2021
    Traits That Make You  a Great Nurse Also Lead to Success as a Clinical Trials PI
    Oncology clinical trials

    Traits That Make You a Great Nurse Also Lead to Success as a Clinical Trials PI

    Clinical trials are led by a principal investigator (PI) with a research team that may include physicians, nurses, social workers, and other healthcare professionals. PIs can represent a variety of disciplines, and nurse scientists often hold that role.

    December 14, 2021
    Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients
    Oncology clinical trials

    Use ClinicalTrials.gov to Find the Right Cancer Research Studies for Your Patients

    Among the many online resources for identifying cancer clinical trials, including the National Cancer Institute (NCI), NCI-designated cancer centers or academic cancer centers, and drug and biotechnology companies, ClinicalTrials.gov may be the most comprehensive as a one-stop shop for patients and providers to find publicly and privately supported trials for patients.

    December 09, 2021
    Patients Cope With Intense Emotions After Clinical Trial Withdrawal
    Oncology clinical trials

    Patients Cope With Intense Emotions After Clinical Trial Withdrawal

    When withdrawing from a clinical trial, patients experience a spectrum of emotions ranging from regret, urgency, frustration—and trust in their healthcare professionals, like oncology nurses, according to the results of a study published in JAMA Network Open.

    December 08, 2021
    Not Eligible for Trials? Expanded Access May Give Patients Options for Investigational Products
    Oncology clinical trials

    Not Eligible for Trials? Expanded Access May Give Patients Options for Investigational Products

    The U.S. Food and Drug Administration’s (FDA’s) expanded access program is a pathway for providers to request using an investigational medical product to treat a patient with an immediately life-threatening or serious disease or condition outside of clinical trials when no comparable or satisfactory alternative therapy options are available. FDA’s Project Facilitate, a comprehensive program within FDA’s Oncology Center of Excellence, makes the pathway more accessible by assisting oncology healthcare professionals in submitting single-patient oncology expanded access applications.

    December 07, 2021
    Nursing Roles in Clinical Trials
    Oncology nursing roles

    Nursing Roles in Clinical Trials

    Clinical trials provide evidence to support what you do in your work as a nurse every day. They are tools to discover new therapies and identify side effects while considering patient-specific factors like age, comorbidities, race, and sex. They build support for best practices in treatment and patient care.

    December 07, 2021
    Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance
    Cancer research

    Scientists Identify Protein Implicated in Tumor Growth, Treatment Resistance

    A protein called AMBRA1 may be to blame for tumor resistance to CDK4/6 inhibitors, according to results from international teams of researchers that were reported in Nature.

    July 21, 2021
    Immunotherapy Extends Survival in Uveal Melanoma
    Research

    Immunotherapy Extends Survival in Uveal Melanoma

    Patients with uveal melanoma who were treated with tebentafusp, an investigational immunotherapy, lived a median 5.7 months longer than those in comparison groups, researchers reported in study findings presented at the American Association for Cancer Research 2021 annual meeting. 

    June 23, 2021
    Oncology clinical trials

    How to Overcome Underrepresentation in Oncology Clinical Trials and Research Studies

    For the findings to be usable, healthcare research clinical trials must accrue participants that accurately represent the general population to which the study applies. But that’s easier said than done. During a session on April 27, 2021, for the 46th Annual ONS Congress™, two oncology nurse scientists shared strategies that other researchers can use to overcome disparities in clinical trial study populations.

    April 27, 2021
    FDA Approves Fam-Trastuzumab Deruxtecan-Dxki for HER2-Positive Gastric Adenocarcinomas
    Cancer treatments

    FDA Approves Fam-Trastuzumab Deruxtecan-Dxki for HER2-Positive Gastric Adenocarcinomas

    On January 15, 2021, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

    January 19, 2021
    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso®) as adjuvant therapy after tumor resection for patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. 

    December 21, 2020
    Telegenetic Counseling Bridges Geographic Barriers and Minimizes Distress
    Research

    Telegenetic Counseling Bridges Geographic Barriers and Minimizes Distress

    Our 2009–2014 study, Bridging Geographic Barriers: Remote Cancer Genetics Counseling for Rural Women, also known as the REACH Project (Risk Education and Assessment for Cancer Heredity), was the first randomized, noninferiority trial of telephone-based BRCA1 and BRCA2 counseling and testing that used a population-based traceback approach to identify and counsel both rural and urban women who were at increased risk for hereditary breast and ovarian cancer but had not received genetic counseling or testing.

    December 10, 2020
    Study Links HPV Vaccine to Reduced Rates of Cervical Cancer
    Research

    Study Links HPV Vaccine to Reduced Rates of Cervical Cancer

    Cervical cancer rates have dropped more than 90% among women who received the human papillomavirus (HPV) vaccine, according to the results of a Swedish study published in the New England Journal of Medicine. Global health leaders are calling it a milestone study. 

    October 23, 2020
    Radiation Clinical Trials Must Evolve to Include Patient-Reported Outcomes
    Radiation therapy

    Radiation Clinical Trials Must Evolve to Include Patient-Reported Outcomes

    Prostate cancer is one of the most common cancers treated with radiotherapy (RT). Conventional RT for low-risk patients usually involves 40–45 treatments given over eight or nine weeks. Several studies suggest that hypofractionated RT—fewer treatments but with a higher dose per treatment—may produce a similar survival benefit. When two treatments have similar survival outcomes, the decision process looks at symptom profiles, quality of life, and cost.

    October 14, 2020
    The Case of the HPV-Positive Perk
    Clinical practice

    The Case of the HPV-Positive Perk

    Warren is a 50-year-old man recently diagnosed with human papillomavirus (HPV)-positive oropharyngeal cancer. He and his wife meet with a radiation oncologist and develop a plan of care. Lisa, the radiation oncology nurse, meets with the couple to provide education and answer questions. Darren tells her that two of his “hard living” uncles died from head and neck cancer and the treatment was horrible. He says, “I’ve only had two sexual partners and never smoked—is this cancer really worth treating?”

    July 21, 2020
    Prostate Cancer Clinical Trials Don’t Reflect Racial Diversity—And It’s Getting Worse Over Time
    Cancer research

    Prostate Cancer Clinical Trials Don’t Reflect Racial Diversity—And It’s Getting Worse Over Time

    More than 96% of participants in prostate cancer clinical trials are non-Hispanic white men even though non-Hispanic black men represent 22% of prostate cancer diagnoses, researchers reported in Cancer Epidemiology, Biomarkers, and Prevention. Even more critical, enrollment rates of black or African American men have been declining since 1995.

    July 08, 2020
    Geographic Disparities Affect Clinical Trials Participation for Minorities
    Cancer health disparities

    Geographic Disparities Affect Clinical Trials Participation for Minorities

    Clinical trials are a vital part of moving cancer care into the future. Enrollment and participation provide patients with cutting-edge treatments and build the knowledge base for clinicians to offer the best possible care available. Patients who enroll in clinical trials receive a high quality of care, increased surveillance, and a greater adherence to treatment protocols because of the nature of scientific study. However, Latino and African American participation in clinical trials is low compared to their representation in the U.S. population.  

    April 07, 2020
    FDA Issues Guidance for Conducting Clinical Trials During COVID-19
    U.S. Food and Drug Administration (FDA)

    FDA Issues Guidance for Conducting Clinical Trials During COVID-19

    On March 18, 2020, the U.S. Food and Drug Administration (FDA) issued a guidance for industry, investigators, and institutional review boards conducting clinical trials during the COVID-19 coronavirus pandemic in recognition that it may affect the conduct of clinical trials of medical products, including drugs, devices, and biologic products.

    March 25, 2020
    Clinical Trial Participants Average  6.5 Years Younger Than Actual Cancer Populations
    Research

    Clinical Trial Participants Average 6.5 Years Younger Than Actual Cancer Populations

    For the four most common cancer sites (breast, prostate, colorectal, and lung cancer), the median age of patients in clinical trials is an average of 6.5 years younger than the median age of patients diagnosed with that cancer. And the age disparity is worsening, researchers reported in JAMA Oncology. 

    August 07, 2019
    New CAR T-Cell Targets Show Safe Results in Early Clinical Trials
    Research

    New CAR T-Cell Targets Show Safe Results in Early Clinical Trials

    Findings from two phase I clinical trials presented at the American Association for Cancer Research 2019 annual meeting indicate that targeting CAR T cells against mesothelin for advanced solid tumors and HER2 for advanced sarcoma is safe and shows clinical antitumor activity.

    June 26, 2019
    ONS Congress

    Nurses Must Be Pharmacovigilant With Emerging Cancer Treatments

    The field of cancer care is changing and evolving like never before. In 2018, the U.S. Food and Drug Administration (FDA) approved a number of new biosimilars, targeted agents, and agents that target certain mutations regardless of tumor site. New requirements for accreditation and reimbursement mean oncology nurses are being used in a growing number of new or developing roles including navigation and survivorship. On Thursday, April 11, 2019, Kathleen Wiley, RN, MSN, AOCNS®, addressed these emerging trends and more in a clinical chat at the ONS 44th Annual Congress in Anaheim, CA.

    April 11, 2019
    Drug Pricing Talks; Clinical Trial Barriers; Survivorship Challenges
    Prescription medication

    Drug Pricing Talks; Clinical Trial Barriers; Survivorship Challenges

    Rising prescription medication costs has been a major focus area for both the Trump administration and the 116th Congress. In January 2019, both the House and Senate committees of jurisdiction held public hearings on soaring drug costs. Despite constant media attention and mounting pressure from government officials, no pharmaceutical company executives chose to testify. Congress threatened to subpoena the industry if it happened again.

    February 25, 2019
    VA and NCI Collaborate on Access to Cancer Clinical Trials
    National Cancer Institute (NCI)

    VA and NCI Collaborate on Access to Cancer Clinical Trials

    A new cross-government program is underway to improve veterans’ access to clinical cancer trials. Together with the National Cancer Institute (NCI), the Department of Veterans Affairs (VA) Interagency Group to Accelerate Trials Enrollment launched in 12 VA facilities in summer 2018.

    September 12, 2018
    How Is CTCAE Improving Research and Patient Care?
    Oncology clinical trials

    How Is CTCAE Improving Research and Patient Care?

    The Common Terminology Criteria for Adverse Events (CTCAE) is a list of adverse event (AE) terms most often encountered in oncology. It’s been in ongoing development since the 1980s and was previously referred to as the Common Toxicity Criteria. Through continual development and support from the National Cancer Institute’s Cancer Therapy Evaluation Program, CTCAE aids in the documentation and analysis of adverse events in oncology-related clinical trials.  

    August 01, 2018
    Patient on a Clinical Trial Needs to Visit the Dentist
    Oncology clinical trials

    What Would You Say if Your Patient on a Clinical Trial Needs to Visit the Dentist?

    One of your patients is enrolled in a clinical trial and is scheduled to receive an investigational drug today. She reports a cracked tooth and asks if it’s okay to get dental work. What should you tell her? 

    A. To Set up an appointment with her dentist between treatment cycles. 

    B. To check with her research team before setting up a dental appointment. 

    C. Not to have any dental work done since she’s on a clinical trial.  

    D. Have her tooth fixed right away and let the research team know if you have any problems. 

    July 17, 2018
    Consider a Role in Clinical Trials Research as an Evolution of Your Nursing Career
    Oncology clinical trials

    Consider a Role in Clinical Trials Research as an Evolution of Your Nursing Career

    Nurses can do it all. After all, the often-unsung heroes of health care use their unique skills to positively impact patients and their families in more ways than most people can ever imagine. Unfortunately, role confusion and a lack of awareness of a vital specialty have led to a dire need of nurses in clinical trials.

    July 13, 2018
    Communication, Organization Are Top Drivers of Oral Adherence in Clinical Trials
    Oral adherence

    Communication, Organization Are Top Drivers of Oral Adherence in Clinical Trials

    Oncology nurses know the challenges of patient adherence to oral cancer therapies. Every dose a patient misses can affect their outcomes and chance of survival. But in clinical trials, oral adherence has even broader implications: when a study is evaluating the efficacy of a drug, it depends on study participants taking it exactly as the trial outlines.

    July 10, 2018
    What You Need to Know About Obtaining Informed Consent
    Oncology clinical trials

    What You Need to Know About Obtaining Informed Consent

    Informed consent is a comprehensive process as opposed to a check mark on a list of tasks to complete prior to starting cancer therapy. The American Society of Clinical Oncology/ONS Chemotherapy Administration Safety Standards explain that informed consent provides a patient with “sufficient information about the disease diagnosis and treatment options so that the individual can make a reasonable decision about treatment on the basis of an understanding of the potential risks and anticipated benefits of the treatment.”

    May 28, 2018
    Oncology clinical trials

    Geographic Health Disparities Affect Access to Clinical Trials

    Geographic location impacts life expectancy and even cancer care. Marylynn Ostrowski Ireland, PhD, of Viability, Inc., and Deborah Watkins Bruner, PhD, RN, FAAN, of Emory University in Atlanta, GA, discussed geographic health disparities during a session at the 43rd Annual Congress in Washington, DC.

    May 19, 2018
    The Case of the Pain Paradox: Follow-Up and Clinical Trial
    Pain management

    The Case of the Pain Paradox: Follow-Up and Clinical Trial

    The January 2018 case study introduced Vince, a 55-year-old man receiving chemotherapy and radiation for recurrent bladder cancer. He suffers from chronic back pain because of spinal stenosis and has been on opioid therapy for nearly two years.

    March 20, 2018
    How the FDA Provides New Approaches to Old Problems
    U.S. Food and Drug Administration (FDA)

    How the FDA Provides New Approaches to Old Problems

    Every quadrennial presidential cycle, as the newly elected leader moves into the Oval Office, he selects a core group of advisors who are philosophically aligned and eager to make changes in the federal government’s process. However, this is often not as simple as the new administration believes.

    November 20, 2017
    Sheila Prindiville
    Oncology clinical trials

    How Do You Find Clinical Trials Through the NCI’s Advanced Clinical Trials Search?

    As part of the National Cancer Moonshot Initiative and in collaboration with the Presidential Innovation Fellows, the National Cancer Institute (NCI) developed and launched a new website in 2016. It provides user-friendly access to the repository of abstracts of cancer clinical trials that NCI supported.

    September 05, 2017
    oncology clinical trial nurses impact cancer care
    Oncology clinical trials

    Oncology Nurses Drive Change In Cancer Care With Clinical Trials

    Clinical trials are responsible for discovering new treatments for cancer as well as the continued evolution of standards of care in clinical practice. Nationally, less than 5% of all eligible adult patients with cancer enroll in clinical trials. Additionally, it takes a drug an average of six to eight years from when it is first introduced in trials to become fully available to all patients who could benefit from it.

    September 05, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Halts Two Clinical Trials Evaluating Pembrolizumab in Patients With Multiple Myeloma

    On August 31, 2017, based on data from two recently halted clinical trials, the U.S. Food and Drug Administration (FDA) is issuing a statement to inform the public, healthcare professionals, and oncology clinical investigators about the risks associated with the use of Keytruda (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. Keytruda (pembrolizumab) is not approved for treatment of multiple myeloma.

    August 31, 2017
    Patients Randomized to Cancer Clinical Trials
    National Cancer Institute (NCI)

    How Are Patients Randomized to Cancer Clinical Trials?

    Before any new treatment or approach is used with people in clinical trials, researchers work to understand its effects on cancer cells in the lab and in animals. Researchers design cancer clinical trials to test new ways to treat, detect, diagnose, and prevent cancer, and manage symptoms of cancer and side effects from treatment.

    August 10, 2017
    Cancer Clinical Trials
    Oncology clinical trials

    How One Institution Improved Accrual to Cancer Clinical Trials

    One of the key factors to a cancer clinical trial’s success is the ability to enroll an adequate number of patients in an appropriate timeframe. Identifying barriers to slow accrual and ways to address them can help researchers and nurse scientists make big steps in the fight against cancer in the era of the National Cancer Moonshot Initiative.

    May 17, 2017
    ONS Congress

    How Oncology Nurses Can Contribute to Immunotherapy Clinical Trials

    Using the human immune system to target cancer has made tremendous strides in recent years. Jaruska Naidoo, MBBCh, from the Sidney Kimmel Comprehensive Cancer Center, and Joanne Riemer, RN, BSN, from Johns Hopkins University, discussed the progress made in immunotherapy and how nurses play a role in clinical trials during a session at the 42nd Annual Congress in Denver, CO.

    May 06, 2017
    Oncology clinical trials

    Why Does the FDA Place Clinical Holds on Investigational New Drug Clinical Trials?

    You have a patient with cancer who is participating in a clinical trial. The patient has just been told that the trial has been placed on a clinical hold. What does that mean? What should you say to your patient?
    December 06, 2016
    Cancer moonshot

    Vice President Announces Strategic Goals, New Partnerships for Cancer Moonshot

    On October 17, 2016, Vice President Joe Biden addressed President Obama and the rest of the United States as he presented the National Cancer Moonshot taskforce’s report of the work that’s been accomplished since its inception in January 2016. The report highlights a number of strategic initiatives, including the 10 recommended areas of scientific advancement the Blue Ribbon Panel identified in September.
    October 19, 2016
    Health Policy

    HHS Requires More Information on Clinical Trials to Be Public

    In a move to make government sponsored clinical trials publicly known and easily found, the Department of Health and Human Services (HHS) announced a new process for submitting and releasing clinical trials on the government's new clinical trials website.
    October 06, 2016
    Cancer treatments

    Poliovirus May Be Key to Treating Glioblastoma

    A phase I study has shown that a small group of patients with recurrent glioblastoma who received treatment with a modified form of poliovirus showed survival improvement over historical controls. The findings, which were not peer reviewed, were presented at the 2016 American Society of Clinical Oncology annual meeting.
    August 16, 2016
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲